ArticleFrontiers in oncology2026
Liver resection is associated with better survival than TACE for hepatocellular carcinoma modestly beyond Milan criteria: a multicenter propensity-matched analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC) within extended transplant criteria, but it is available to only a minority of patients. The optimal alternative treatment strategy for patients with HCC beyond the Milan criteria (BMC) but still within extended transplant frameworks-defined in this study as modestly beyond the Milan criteria (MBMC)-remains unclear. This study aimed to compare the overall survival (OS) associated with liver resection (LR) versus transarterial chemoembolization (TACE) in patients with MBMC-HCC. Methods: Between January 2010 and October 2021, 1,110 patients with MBMC-HCC and Child-Pugh A liver function from 15 hepatobiliary centers in China were included, including 424 who underwent LR and 686 who received TACE. Overall survival was compared between groups using propensity score matching (PSM). The findings were further evaluated in additional BMC-HCC cohorts defined according to other extended transplant criteria, including the Asan criteria, up-to-7 criteria, the French AFP model, and the Metroticket 2.0 model. Results: In the multicenter MBMC-HCC cohort, as well as in the additional BMC-HCC cohorts, LR was associated with significantly longer overall survival than TACE (all log-rank P < 0.001). After 1:1 PSM, the survival advantage of LR remained consistent. Multivariable analyses and subgroup analyses across tumor burden and other baseline factors showed similar trends, although these findings should be interpreted with caution. Conclusions: LR was associated with significantly better overall survival than TACE in selected patients with MBMC-HCC. These findings support further prospective studies to clarify the role of LR in this population when transplantation is not available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.